webbanner.jpg

Content from Spring 2020 Meeting of Oncology Investor Conference Series

(& Additional Immunology, COVID, and Infectious Disease Track)

NORMAL AND NEOPLASTIC STEM CELLS
Dr. Irving Weissman, Director, Institute for Stem Cell Biology & Regenerative Medicine AND Stanford Ludwig Center for Cancer Stem Cell  Research and Medicine
COVID: OUR LIFE SCIENCES SPUTNIK MOMENT
Dr. Ron DePinho, Immediate Past President, MD Anderson Cancer Center
TRANSFOMRATION IN CANCER DIAGNOSIS AND TREATMENT IN 2020
CMO, National Foundation for Cancer Research
Frm President, Emory & McGill Cancer Centers
Director, Darwin Institute
APPLYING FINANCIAL ENGINEERING TO CANCER
Dr. Andrew Lo, Director, Laboratory for Financial Engineering, MIT
PANEL: COVID'S AFFECTS ON CLINICAL TRIALS
Moderated By: Roy Herbst, Co-Head of Immunology at Yale Cancer Center
ENHCANCED DRUG DEVELOPMENT USING DRUG MECHANISM BIOMARKERS
Director DCTD Program Pharmacodyrnamic Biomarkers
REPURPOSING THE POLIO VACCINE IN THE WAR AGAINST COVID
Dr. Robert Gallo, Co-Founder and Director, The Institute of Human Virology (IHV) and Co-Founder HIV Virus
COVID: OUR LIFE SCIENCES SPUTNIK MOMENT
Dr. Jerome Kim, Director General of the International Vaccine Institute
BIOSECURITY: A MULTI-DIMENSIONAL CHALLENGE OF ESCALATING COMLEXITY AND URGENCY
George Poste, Professor, ASU; Former Head of R&D, GSK; Defense Science Board of the U.S. Department of Defense

Spring 2020 Meeting of Oncology Investor Conference Series Scheduled for Monday, March 30 - Thursday, April 1

Speakers Include: Jim Allison, Greg Simon

The Spring 2021 Meeting of the Oncology Investor Conference Series will be hosted virtually Monday, April 29 – Thursday March 1, 2021.  The National Foundation for Cancer for Research is the Platinum Presenting Sponsor.

Over 90 cancer startups, early pre-clinical through clinical, public and private, are expected to present, and over 200+ investors spanning venture, public funds, foundations, family offices, angels, and government grant making entities are expected to attend.

Speakers include: Dr. Jim Allison, Dr.  Lynda Chin, Dr. Steven Ferguson, Dr. Keith Flaherty, Dr. Priti Hegde, Dr. Brian Lelyand Jones, Dr. Jerome Kim, Dr. Heidi Larson, Dr. Paul Marik, Dr. Philip Friedlander, Dr. Wayne Froland, Dr. Sung Poblete, Greg Simon, Dr. Alfred Slanetz, and Dr. Pam Sharma.

NanoView: Driving a Better Understanding of Extracellular Vesicles (EVs)

An exponentially growing body of research has indicated that exosomes are involved in cellular communication and a better understanding of their function may have a significant impact on diseases like cancer, neurodegenerative disorders, and cardiovascular disease.  Given their circulation in all biological fluids, exosome-based liquid biopsies are being investigated for early disease detection and treatment. Exosomes are also being studied as next generation therapeutics due to their long half-lives in vivo and capacity to deliver therapeutic cargo inside cells.

NanoView Biosciences, founded in 2015 based on research based at Boston University, manufactures and sells products and services which enable researchers in life science to better understand the biology of extracellular vesicles (EVs) including exosomes.

Vivan Therapeutics’s Personal Discovery Process: Applications for Patient Treatment & Biopharma Discovery & Development

Personalising cancer treatments via individual patient tumour genomics is challenging due to limitations in modelling tumour complexity. Up to 75% of first line cancer treatments fail costing us $391bn annually. Oncologists have never had an alternative but to treat by trial and error. Clinicians determine therapy based on only one or two known cancer mutations. Consequently, this approach has not improved traditional standard of care outcomes. 

Vivan Therapeutics (formerly My Personal Therapeutics), offers personalized cancer therapeutics utilizing technology developed and licensed exclusively from Mt. Sinai Medical Center.  The Company identifies personalized cancer treatments for patients based on their tumor genetics. For each patient, Vivan buildS a genetically matched fruit fly model of the tumor, which is used for large-scale drug screening to find novel and effective drug combinations. 

EarlyDx: Detecting and Locating Cancer Early

EarlyDiagnostics, Inc. (“EarlyDx”), a Los Angeles based liquid-biopsy and big data company, is developing a blood-based test, the CancerRadar Test, for not only detecting cancer at early stages but also pinpointing its location.

 

According to 2019 Cancer Statistics published by CA: A cancer Journal for Clinicians, the 5-year survival is 90.5% for all cancers when diagnosed early (localized stage) but only 36% for cancers diagnosed at all stages. Traditional imaging-based early cancer diagnosis modalities only cover a handful of cancer types and remain mostly unchanged in the past decades. A new approach, called liquid biopsy, analyzing the tumor signal in a patient’s blood, is expected to revolutionize the early diagnosis market.

EarlyDxCloud.png

PinotBio – Targeting Relapsed/Refractory Cancer with well-designed multi-target agents

PinotBio, Inc., a South Korean-based clinical stage biotech, is seeking to treat relapsed/refractory cancers by applying “well-designed multi-target anti-cancer treatments”. The novel anti-cancer therapeutics of PinotBio utilize well-known and well-established cancer treatment targets, such as DNA Methyltransferase 1 (DNMT1) and Topoisomerase 1. These therapeutics block one or more resistant pathways to overcome the development of resistance. As a result, PinotBio’s anti-cancer agents show stronger efficacy in various preclinical models and show the potential to overcome cancer resistance.

PinotBio attempts to overcome these problems by utilizing the novel concept of well-designed multi-target inhibition.

Immunicom – CE Mark Cleared Therapeutic Device Addresses Cancer in a Novel Way

Cancer immunotherapy has traditionally been both expensive, and especially in the case of T-cell therapy, riddled with toxic side effects.  Immunicom, a privately held, therapeutic device company based in San Diego, CA, is seeking to address these, as well as many of the other drawbacks of current immunotherapies.  

The company received European regulatory approval through a CE Mark for its ImmunopheresisTM technology in 2020, after conducting trials in Europe at the University of Krakow and other leading sites.  Immunicom’s ImmunopheresisTM platform technology works by using molecular filters to capture from the patient’s blood, specific, immune suppressing factors released by solid tumors.  Immunicom has been classified by the FDA as a “Breakthrough Technology”, giving it a potential fast track through its US regulatory approval process. 

immunicom.jpg

Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant 

Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care.

A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard of care in this patient population; Phase III TrilynX study initiated in September 2020.

Merck KGaA, Darmstadt, Germany gains exclusive global development and commercialization rights; Debiopharm to receive €188 million upfront and up to €710 million in milestone, as well as royalty payments.

Xevinapant800-600-don-t-use.jpg